Oct 16, 2020 | MedBen Rx, Prescription drugs, Rx Spending, Savings, Transparency
A National Alliance of Healthcare Purchaser Coalitions survey asked employers what they thought were the greatest threats to coverage affordability. Their responses… and how MedBen counters these concerns with proven saving solutions: Drug prices are a threat to...
Sep 5, 2020 | Prescription drugs, Specialty Drugs
Myalept tops the list of the most expensive drugs currently sold in the United States, as compiled by GoodRx. Used to treat leptin deficiency, Myalept carries a list price of $71,306 for a 30-day prescription. Mavenclad, a multiple sclerosis treatment, follows at...
Aug 7, 2020 | MedBen Rx, MedBen Rx Advocate, Pharmacy Benefits Manager (PBM), Prescription drugs, Spread Pricing
Three-quarters of MedBen clients have switched to MedBen Rx Advocate for their pharmacy benefits. “And when they do, they are saving money,” said Brian Fargus, MedBen’s VP of Sales & Marketing. In 2019 MedBen Rx clients saved 12.0% average cost per script, and an...
May 17, 2020 | MedBen Rx, MedBen Rx Advocate, MedBen Rx Alliance, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Savings
Three-quarters of MedBen clients use MedBen Rx prescription programs and are seeing the benefits first-hand. By utilizing our forward-thinking pharmacy solutions, these groups realized an average savings of 14.8% per employee per year, compared to those using other...
Mar 6, 2020 | MedBen Rx, Prescription drugs
With the novel coronavirus COVID-19 a constant topic in the news nowadays, many consumers are stocking up on various drugs. MedBen is recommending no change to the current prescription drug refill guidelines for our clients and here’s why: Most wholesalers have a good...
Feb 8, 2020 | MedBen Rx, MedBen Rx Advocate, Pharmacies, Pharmacy Benefits Manager (PBM), Pharmacy Services Administrator (PSA), Prescription drugs, Rx Costs, Rx Spending, Savings, Transparency
MedBen Rx Advocate offers clients true transparency by removing the ability for pharmacy benefits managers to manipulate drug pricing. By using fee-based pricing, we avoid the margin markups that PBM “middlemen” use to inflate their profits. The Hill reports that...
